Article Text

other Versions

PDF
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
  1. M JL Peters (mjl.peters{at}vumc.nl)
  1. VU university medical center, Netherlands
    1. D PM Symmons (deborah.symmons{at}manchester.ac.uk)
    1. ARC Epidemiology Unit, United Kingdom
      1. D McCarey (david.mccarey{at}northglasgow.scot.nhs.uk)
      1. Glasgow Royal Infirmary, Glasgow, United Kingdom
        1. B AC Dijkmans (secr.reumatologie{at}vumc.nl)
        1. Free University Hospital, Netherlands
          1. P Nicola (pnicola{at}fm.ul.pt)
          1. Department of Preventive Medicine, Faculty of Medicine of Lisbon, Lisbon, Portugal
            1. T K Kvien (t.k.kvien{at}medisin.uio.no)
            1. Diakonhjemmet Hospital, Norway
              1. I B McInnes (i.mcinnes{at}clinmed.gla.ac.uk)
              1. Centre for Rheumatic Diseases, University of Glasgow, United Kingdom
                1. H Haentzschel (holm.haentzschel{at}medizin.uni-leipzig.de)
                1. Rheumazentrum am Universitätsklinikum Leipzig, Germany
                  1. M A Gonzalez-Gay (miguelaggay{at}hotmail.com)
                  1. Hospital Xeral-Calde, Lugo, Spain, Spain
                    1. S Provan (sella{at}mailbox.as)
                    1. Department of Rheumatology, Diakonhjemmet Hospital, Norway
                      1. A G Semb (anne.semb{at}yahoo.no)
                      1. Diakonhjemmet sykehus, Norway
                        1. P Sidiropoulos (sidiropp{at}med.uoc.gr)
                        1. Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Greece
                          1. G Kitas (gd.kitas{at}dgoh.nhs.uk)
                          1. Dudley Group of Hospitals NHS Trust Russells Hall Hospital, United Kingdom
                            1. Y M Smulders (y.smulders{at}vumc.nl)
                            1. Department of Internal Medicine, VU University Medical Center, Netherlands
                              1. M J Soubrier (msoubrier{at}chu-clermontferrand.fr)
                              1. Service de Rhumatologie. Hopital G Montpied, France
                                1. Z Szekanecz (szekanecz.zoltan{at}med.unideb.hu)
                                1. University of Debrecen Medical Center, Hungary
                                  1. N G Sattar (nsattar{at}clinmed.gla.ac.uk)
                                  1. University of Glasgow, Norway
                                    1. M T Nurmohamed (m.nurmohamed{at}janvanbreemen.nl)
                                    1. Jan van Breemen Institute & VU University Medical Center, Netherlands

                                      Abstract

                                      Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

                                      Methods: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing 9 European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's 'standardised operating procedures', the multidisciplinary steering committee formulated evidence-based and expert opinion based recommendations for CV risk screening and management in patients with inflammatory arthritis.

                                      Results: Annual CV risk assessment using National Guidelines is recommended for all RA patients and should be considered for all AS and PsA patients. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk.

                                      Conclusions: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA on the other hand, as evidence for an increased CV risk is most compelling for RA.

                                      Statistics from Altmetric.com

                                      Request permissions

                                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.